- Trial phase
- Phase 2
- Time to market
- Not stated
- Why 4/10
- No PDUFA date or pivotal Phase 3 readout is scheduled; the next hard catalyst is the AHA 2026 Scientific Sessions podium presentation of ELPIS II secondary endpoint data (date TBD), but this is a data presentation, not a binary regulatory or pivotal readout. The primary binary catalyst (ELPIS II topline) already passed on Sept 16, 2026 with a negative outcome. ImpactScore of 4 reflects a mid-stage pipeline with no imminent binary catalyst and significant uncertainty around the company's strategic review and cash runway.
The next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.
Price Chart
Executive Summary
Laromestrocel (Lomecel-B) is Longeveron's allogeneic mesenchymal stem cell therapy being investigated across multiple indications. The lead program, ELPIS II Phase 2b in hypoplastic left heart syndrome (HLHS), missed its primary endpoint (RVEF at 12 months, p=0.8336) in September 2026, triggering a strategic review of all options. Updated secondary endpoint data announced today (Oct 26, 2026) showed a statistically significant reduction in major adverse cardiac events (MACE, p=0.043), earning a Late-Breaking Science podium at AHA 2026. The drug also has Phase 2b data in aging frailty (published in Cell Stem Cell, Feb 2026) and Phase 2a data in Alzheimer's (published in Nature Medicine, March 2025). However, with cash runway extending only into Q4 2026, the CMO's recent departure, and the company exploring a formal strategic review, the company faces an uncertain path forward.
How It Works
Laromestrocel is a living cell therapy made from mesenchymal stem cells (MSCs) isolated from the bone marrow of young, healthy adult donors. These cells are grown in a lab and then infused into patients intravenously. MSCs are the body's natural repair cells, they can reduce inflammation, promote tissue repair, and modulate the immune system. The idea is that infusing large numbers of these cells can help the body heal itself in conditions ranging from heart defects in newborns to age-related frailty and Alzheimer's disease.
Trial Status
ELPIS II (HLHS) Phase 2b topline readout completed Sept 2026, primary endpoint missed; updated secondary analysis (MACE) announced Oct 26, 2026. CLEAR MIND (Alzheimer's) Phase 2a completed, published in Nature Medicine March 2025. Frailty Phase 2b completed, published in Cell Stem Cell Feb 2026. Pediatric DCM Phase 2 IND approved 2025, trial ongoing.
The Two-Sided Case
Upcoming Catalysts
- AHA 2026 Scientific Sessions Late-Breaking Science podium presentation of ELPIS II secondary endpoint data (date TBD, likely November 2026)
- FDA meeting to discuss potential path forward for HLHS program
- Outcome of strategic alternatives review (potential sale, partnership, or financing)
- Q3 2026 earnings report and cash runway update
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Longeveron Press Release LGVN ·Originating report